These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21422739)

  • 1. Development of modified nucleosides that have supremely high anti-HIV activity and low toxicity and prevent the emergence of resistant HIV mutants.
    Ohrui H
    Proc Jpn Acad Ser B Phys Biol Sci; 2011; 87(3):53-65. PubMed ID: 21422739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity.
    Ohrui H
    Chem Rec; 2006; 6(3):133-43. PubMed ID: 16795005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of 4'-C-substituted nucleosides for the treatment of HIV-1.
    Hayakawa H; Kohgo S; Kitano K; Ashida N; Kodama E; Mitsuya H; Ohrui H
    Antivir Chem Chemother; 2004 Jul; 15(4):169-87. PubMed ID: 15457679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma.
    Ohrui H; Kohgo S; Hayakawa H; Kodama E; Matsuoka M; Nakata T; Mitsuya H
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(10-12):1543-6. PubMed ID: 18066823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses.
    Schinazi RF; Hernandez-Santiago BI; Hurwitz SJ
    Antiviral Res; 2006 Sep; 71(2-3):322-34. PubMed ID: 16716415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2'-Deoxy-4'-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against all HIV-1 strains, favorable toxic profiles and stability in plasma.
    Ohrui H; Kohgo S; Hayakawa H; Kodama E; Matsuoka M; Nakata T; Mitsuya H
    Nucleic Acids Symp Ser (Oxf); 2006; (50):1-2. PubMed ID: 17150787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of 2',3'-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V).
    Choo H; Chong Y; Chu CK
    Bioorg Med Chem Lett; 2003 Jun; 13(12):1993-6. PubMed ID: 12781181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates.
    Mackman RL; Boojamra CG; Prasad V; Zhang L; Lin KY; Petrakovsky O; Babusis D; Chen J; Douglas J; Grant D; Hui HC; Kim CU; Markevitch DY; Vela J; Ray A; Cihlar T
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6785-9. PubMed ID: 18029175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.
    Miller MD; Margot NA; Hertogs K; Larder B; Miller V
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1025-8. PubMed ID: 11562951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.
    Mackman RL; Zhang L; Prasad V; Boojamra CG; Douglas J; Grant D; Hui H; Kim CU; Laflamme G; Parrish J; Stoycheva AD; Swaminathan S; Wang K; Cihlar T
    Bioorg Med Chem; 2007 Aug; 15(16):5519-28. PubMed ID: 17562366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis.
    Harris KS; Brabant W; Styrchak S; Gall A; Daifuku R
    Antiviral Res; 2005 Jul; 67(1):1-9. PubMed ID: 15890415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
    Domaoal RA; Demeter LM
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D- and L-2',3'-didehydro-2',3'-dideoxy-3'-fluoro-carbocyclic nucleosides: synthesis, anti-HIV activity and mechanism of resistance.
    Wang J; Jin Y; Rapp KL; Schinazi RF; Chu CK
    J Med Chem; 2007 Apr; 50(8):1828-39. PubMed ID: 17373782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, efficient synthesis, and anti-HIV activity of 4'-C-cyano- and 4'-C-ethynyl-2'-deoxy purine nucleosides.
    Kohgo S; Yamada K; Kitano K; Iwai Y; Sakata S; Ashida N; Hayakawa H; Nameki D; Kodama E; Matsuoka M; Mitsuya H; Ohrui H
    Nucleosides Nucleotides Nucleic Acids; 2004; 23(4):671-90. PubMed ID: 15200030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity.
    Vinogradov SV; Poluektova LY; Makarov E; Gerson T; Senanayake MT
    Antivir Chem Chemother; 2010 Oct; 21(1):1-14. PubMed ID: 21045256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro study of resistance-associated genotypic mutations to nucleoside analogs.
    Gashnikova N; Plyasunova O; Kiseleva Y; Fedyuk N; Pokrovsky A
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):991-4. PubMed ID: 14565328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules.
    Hoggard PG; Back DJ
    Curr Opin Infect Dis; 2002 Feb; 15(1):3-8. PubMed ID: 11964899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs.
    Boyer PL; Melody K; Smith SJ; Dunn LL; Kline C; Fischer DK; Dwivedi R; Clark P; Hughes SH; Ambrose Z
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
    Jones LH; Allan G; Barba O; Burt C; Corbau R; Dupont T; Knöchel T; Irving S; Middleton DS; Mowbray CE; Perros M; Ringrose H; Swain NA; Webster R; Westby M; Phillips C
    J Med Chem; 2009 Feb; 52(4):1219-23. PubMed ID: 19175319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Rao A; Balzarini J; Carbone A; Chimirri A; De Clercq E; Monforte AM; Monforte P; Pannecouque C; Zappalà M
    Antiviral Res; 2004 Aug; 63(2):79-84. PubMed ID: 15302136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.